glp-1 receptor agonist and dpp-4 inhibitor combination not recommended Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways do not combine dpp-4 inhibitors
Description
Expanding Applications: Clinical trials are actively investigating the use of GLP-1 RAs for a wider range of conditions, including addiction, kidney disease, and neurodegenerative disorders, based on their broad physiological effects
In some cases, rapid weight gain occurred after discontinuation an indication that long-term success depends heavily on lifestyle
The primary outcome measure for the SELECT trial is the incidence of three-point MACE
The cumulative incidence was 6.7% for semaglutide versus 0.8% for the non-GLP-1 RA group over 36 months
Higher strengths may reach prices of up to $349 monthly
